vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Snail, Inc. (SNAL). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $25.1M, roughly 1.5× Snail, Inc.). Snail, Inc. runs the higher net margin — -3.4% vs -161.8%, a 158.4% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -4.2%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Suzhou Snail Digital Technology Co., Ltd., doing business as Snail, is a Chinese video game company and a Virtual Network Operator headquartered in Suzhou, China, which has branches Snail Games and Snail Mobile. Its division, Snail USA, markets Snail Games products in North America, South America, & Europe. Snail Games products include massively multiplayer online (MMOs), real-time strategy (RTS), and casual games. Its global registered user base has reached over 70 million accounts. The U.S....

IBRX vs SNAL — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.5× larger
IBRX
$38.3M
$25.1M
SNAL
Growing faster (revenue YoY)
IBRX
IBRX
+411.2% gap
IBRX
407.0%
-4.2%
SNAL
Higher net margin
SNAL
SNAL
158.4% more per $
SNAL
-3.4%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
SNAL
SNAL
Revenue
$38.3M
$25.1M
Net Profit
$-61.9M
$-862.2K
Gross Margin
99.0%
38.3%
Operating Margin
-169.0%
-6.0%
Net Margin
-161.8%
-3.4%
Revenue YoY
407.0%
-4.2%
Net Profit YoY
-4.7%
-177.0%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
SNAL
SNAL
Q4 25
$38.3M
$25.1M
Q3 25
$32.1M
$13.8M
Q2 25
$26.4M
$22.2M
Q1 25
$16.5M
$20.1M
Q4 24
$7.6M
$26.2M
Q3 24
$6.1M
$22.5M
Q2 24
$21.6M
Q1 24
$14.1M
Net Profit
IBRX
IBRX
SNAL
SNAL
Q4 25
$-61.9M
$-862.2K
Q3 25
$-67.3M
$-7.9M
Q2 25
$-92.6M
$-16.6M
Q1 25
$-129.6M
$-1.9M
Q4 24
$-59.2M
$1.1M
Q3 24
$-85.7M
$235.1K
Q2 24
$2.3M
Q1 24
$-1.8M
Gross Margin
IBRX
IBRX
SNAL
SNAL
Q4 25
99.0%
38.3%
Q3 25
99.4%
0.1%
Q2 25
99.5%
31.3%
Q1 25
99.6%
29.1%
Q4 24
43.3%
Q3 24
38.6%
Q2 24
37.5%
Q1 24
14.7%
Operating Margin
IBRX
IBRX
SNAL
SNAL
Q4 25
-169.0%
-6.0%
Q3 25
-173.5%
-71.3%
Q2 25
-269.8%
-8.2%
Q1 25
-390.1%
-20.4%
Q4 24
-919.0%
11.5%
Q3 24
-1314.3%
1.8%
Q2 24
12.4%
Q1 24
-15.6%
Net Margin
IBRX
IBRX
SNAL
SNAL
Q4 25
-161.8%
-3.4%
Q3 25
-209.8%
-56.9%
Q2 25
-350.3%
-74.7%
Q1 25
-784.9%
-9.7%
Q4 24
-783.4%
4.3%
Q3 24
-1404.0%
1.0%
Q2 24
10.4%
Q1 24
-12.6%
EPS (diluted)
IBRX
IBRX
SNAL
SNAL
Q4 25
$-0.06
Q3 25
$-0.07
Q2 25
$-0.10
$-0.44
Q1 25
$-0.15
$-0.06
Q4 24
$-0.08
$0.03
Q3 24
$-0.14
$0.01
Q2 24
$0.06
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
SNAL
SNAL
Cash + ST InvestmentsLiquidity on hand
$242.8M
$8.6M
Total DebtLower is stronger
$14.6M
Stockholders' EquityBook value
$-500.5M
$-16.4M
Total Assets
$501.9M
$59.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
SNAL
SNAL
Q4 25
$242.8M
$8.6M
Q3 25
$257.8M
$12.3M
Q2 25
$153.7M
$7.9M
Q1 25
$61.6M
$9.4M
Q4 24
$149.8M
$7.3M
Q3 24
$130.4M
$10.6M
Q2 24
$15.5M
Q1 24
$16.1M
Total Debt
IBRX
IBRX
SNAL
SNAL
Q4 25
$14.6M
Q3 25
$10.5M
Q2 25
$11.8M
Q1 25
$9.0M
Q4 24
$5.7M
Q3 24
$5.7M
Q2 24
$5.8M
Q1 24
$6.5M
Stockholders' Equity
IBRX
IBRX
SNAL
SNAL
Q4 25
$-500.5M
$-16.4M
Q3 25
$-524.3M
$-15.6M
Q2 25
$-570.7M
$-8.0M
Q1 25
$-591.4M
$9.1M
Q4 24
$-489.1M
$9.7M
Q3 24
$-745.1M
$8.2M
Q2 24
$7.9M
Q1 24
$5.6M
Total Assets
IBRX
IBRX
SNAL
SNAL
Q4 25
$501.9M
$59.3M
Q3 25
$519.0M
$51.1M
Q2 25
$402.1M
$58.0M
Q1 25
$303.8M
$64.5M
Q4 24
$382.9M
$62.2M
Q3 24
$364.6M
$66.8M
Q2 24
$75.4M
Q1 24
$78.3M
Debt / Equity
IBRX
IBRX
SNAL
SNAL
Q4 25
Q3 25
Q2 25
Q1 25
0.99×
Q4 24
0.59×
Q3 24
0.70×
Q2 24
0.73×
Q1 24
1.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
SNAL
SNAL
Operating Cash FlowLast quarter
$-70.4M
$-5.3M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
SNAL
SNAL
Q4 25
$-70.4M
$-5.3M
Q3 25
$-68.9M
$6.6M
Q2 25
$-79.7M
$-3.2M
Q1 25
$-85.9M
$764.5K
Q4 24
$-85.1M
$-3.6M
Q3 24
$-98.8M
$-5.0M
Q2 24
$206.6K
Q1 24
$6.8M
Free Cash Flow
IBRX
IBRX
SNAL
SNAL
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
SNAL
SNAL
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
SNAL
SNAL
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
SNAL
SNAL
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-3.21×
Q3 24
-21.05×
Q2 24
0.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

SNAL
SNAL

Pc$14.7M59%
Platform Three$5.2M21%
Platform Two$3.3M13%
Sales Channel Directly To Consumer Mobile Sale$1.6M6%

Related Comparisons